Skip to main content

In Brief This Week: Boston Scientific, Interpace, Human Longevity, and More

NEW YORK (360Dx) – Boston Scientific this week acquired privately held nVision Medical for an upfront cash payment of $150 million, and up to an additional $125 million if potential clinical and commercial milestones are met. nVision has developed a US Food and Drug Administration-cleared device to collect cells from fallopian tubes. The device may be developed into a technology for the earlier diagnosis of ovarian cancer, Boston Scientific said. Initial clinical research has suggested that the platform effectively collects cells, which when tested, correlate with a postsurgery definitive diagnosis of ovarian cancer. Boston Scientific said it intends to perform additional clinical research with the device to establish how the fallopian cells it collects can be used to render a diagnosis prior to surgery.


Interpace Diagnostics said this week that it has entered into an agreement with BJC Healthcare, a St. Louis, Missouri-based nonprofit, integrated healthcare system. The agreement gives all physicians across the BJC system access to Interpace's ThyGenX and ThyraMIR tests for patients with indeterminate thyroid nodules. The tests combine the rule-in properties of next-generation sequencing of a patient's DNA and RNA with rule-out capabilities of a microRNA classifier to provide physicians with clinically actionable test results.


Human Longevity Clinical Labs this week received accreditation from the College of American Pathologists. An onsite inspection was part of the accreditation process, the company said. The lab's records and quality control of procedures for the preceding two years were examined, as were laboratory staff qualifications, equipment, facilities, safety programs and record, and overall management.


CareDx this week said it closed its debt refinancing by entering into a credit agreement with Perceptive Advisors, which provided an initial term loan of $15 million. A second tranche of $10 million is available to CareDx at its option over the next 12 months. Proceeds from the initial $15 million tranche will go toward repayment of CareDx's $11.1 million debt obligation to Danske Bank and the former majority shareholders of Allenex. It will also be used for general corporate purposes. Immediately following the repayment of the debt obligations, CareDx will have cash and cash equivalents of about $22 million, the company said. 


OpGen announced this week that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification and treatment of bacteremia and fungemia in hospital intensive care units in Colombia. Following completion of the trial, the firm established a subsidiary, OpGen Colombia, to commercialize its precision medicine products in Colombia and more broadly through South America.


SeraCare Life Sciences said this week it has partnered with Navican and Royal Philips on the integration of SeraCare's clinical NGS QC solution to support the roll out of Navican’s TheraMap Precision Cancer Care services. The integrated solution merges SeraCare's iQ NGS QC Management software and Philips' IntelliSpace Genomics Platform to automate tracking of all critical genomics workflow QC parameters necessary for monitoring, trending, and reporting on the performance of the TheraMap clinical NGS assay.


Omega Diagnostics said this week it has inked a global distribution deal with Immunodiagnostic Systems for Omega’s allergy assays called Allersys. The two firms will work to commercialize a panel of 51 allergy tests. Omega will also develop new assays for IDS’ instrument menu. Financial and other terms of the agreement were not disclosed.


MDxHealth’s SelectMDx prostate cancer test has been included in the Dutch Diagnosis Related Groups reimbursement system. The DRG reimbursement system was introduced in the Netherlands in 2005 and specifies the reimbursable amounts for 30,000 different treatments. It is regulated by the Dutch Healthcare Authority. Diagnosis and treatment of prostate cancer are reimbursed under the DRG system, MDxHealth said.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.